VivoSeq
Oncology

Childhood Cancer

16

Pipeline Programs

4

Active Trials

10

Companies Involved

Childhood Cancer is an emerging landscape with 16 programs across 10 companies. The most active players are Institut de Recherches Internationales Servier, EMD Serono, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 3 therapies are approved with 2 more in late-stage development.

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

0/100

Mech. Concentration

9/100

Completion Rate

67/100

Attrition Rate

21/100

Programs by Phase

Modality Breakdown

88%

Small molecule

14 of 16 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody16%Protein / enzyme16%

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.

Trial Status

14

clinical trials

Completed6 · 43%
Active, not recruiting3 · 21%
Terminated2 · 14%
Unknown status1 · 7%
Withdrawn1 · 7%
Recruiting1 · 7%

Trial Activity

14 trials

Swiss Childhood Cancer Survivor Study (SCCSS)
Recruiting·UUniversity of Bern·N/A·NCT03297034·4,136 enrolled
Fosamax for Childhood Cancer Survivors
Unknown status··Phase 3·NCT00391404·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)